RGTIQBTSIONQTWSTDNACRSPOKLOSMRBWXTBMNRAPLDCRCLRGTIQBTSIONQTWSTDNACRSPOKLOSMRBWXTBMNRAPLDCRCL
Investment Strategy · Four Frontier Sectors · Twelve Companies

SPECULATIVE
GROWTH
PORTFOLIO

Positioning capital at the frontier — where today's skepticism becomes tomorrow's conviction.

Quantum Computing
RGTI · QBTS · IONQ
Synthetic DNA
TWST · DNA · CRSP
Nuclear Energy (SMR)
OKLO · SMR · BWXT
Crypto Infrastructure
BMNR · APLD · CRCL
SCROLL
01 — Historical Context

THE CASE FOR
SPECULATION

Yesterday's crazy bet is today's blue chip. Every dominant industry was once dismissed as fantasy.

1990sInternet
Then

"No one will shop online." Amazon & eBay were called fads. At the bubble peak, only 14% of internet IPOs were profitable.

Now

E-commerce = $6.3T globally. Amazon is a $2T+ company. The internet underpins the entire global economy.

2000sBiotech
Then

"Gene therapy will never work." Early genomics companies traded at extreme speculative multiples with no revenue.

Now

mRNA technology delivered the COVID vaccine in record time. CRISPR therapies are FDA-approved and treating patients today.

2010sCloud
Then

"Why would any enterprise store data offsite?" Cloud computing was laughed off by traditional IT departments.

Now

AWS alone generates $100B+ annually. Cloud is foundational infrastructure. SaaS commands the highest valuations in markets.

2015+EVs
Then

"Tesla will never compete with Detroit." EV skepticism was near-universal — even among sophisticated investors.

Now

Tesla became a $1T company. Legacy automakers now spending hundreds of billions transitioning entire fleets to electric.

02 — Today's Opportunity

FOUR SECTORS
RHYMING WITH THE PAST

Quantum Computing
Market Opportunity: $1T+ by 2035 (BCG / The Quantum Insider)

Quantum processors will outpace classical computers for drug discovery, cryptography, logistics, and AI optimization. Early commercial contracts are live. DARPA's QBI is validating key players.

⚠ Pre-revenue. Years from utility-scale. IBM and Google competing hard.
Synthetic DNA / Gene Editing
Market: $16.2B (2024) → 17.3% CAGR → $50B+ by 2030

CRISPR gene editing received its first FDA approval in November 2023. Synthetic biology is manufacturing medicine at the DNA level — enabling cures for cancer, diabetes, and blood disorders.

⚠ Long regulatory timelines. Clinical trial failure rates remain high.
Nuclear Energy (SMR)
AI Data Center Power Demand: $2.6T infrastructure surge by 2030

AI data centers, EVs, and re-industrialization are creating unprecedented power demand. Small Modular Reactors are the only 24/7 carbon-free energy solution that scales. Meta, Microsoft, Amazon, and Google are all signing nuclear deals.

⚠ Licensing delays endemic. No revenue yet for pure-plays.
Crypto Infrastructure
Bitcoin: Zero → $1T+ asset class in 15 years. Stablecoins growing rapidly.

Stablecoins are becoming global payment rails. Ethereum is a settlement layer. Infrastructure companies are the picks and shovels of the crypto economy — benefiting regardless of which coin wins.

⚠ Correlated to BTC/ETH price. Regulatory uncertainty remains.
03 — Sector
Quantum Computing
RGTI · QBTS · IONQ
$1T+ TAM by 2035
Quantum computers use qubits that can exist in multiple states simultaneously — solving problems classical computers simply cannot handle at scale.
DARPA's Quantum Benchmarking Initiative (QBI) is validating whether approaches can reach 'utility-scale' by 2033. IonQ is a Stage B participant.
Amazon Braket, Microsoft Azure Quantum, and Google now offer quantum hardware commercially. JPMorgan Chase named quantum a $10B priority.
Still pre-profit across the board. Insiders net-sold ~$615M in shares over the past year. P/S multiples of 30–100x require flawless execution.
RGTINASDAQ
Rigetti Computing

Full-stack quantum computers via superconducting qubits. Partners with AWS Braket & Microsoft Azure. Delivered 84-qubit Ankaa-3. Targeting 1,000+ qubits by end of 2027.

Price
~$15
Target
$43
Upside
+183%
⚠ Revenue declined 17.6% YoY in Q4. Not in DARPA Stage B. High burn rate. Execution risk on qubit scaling roadmap.
QBTSNYSE
D-Wave Quantum

Only publicly-traded quantum company with real commercial revenue. Quantum annealing for optimization problems. Signed €10M Italian government deal and U.S. defense contracts. 14/14 analyst Buy ratings.

Price
~$19
Target
$39
Upside
+106%
⚠ Annealing approach may not scale to general-purpose quantum. Long-term relevance vs gate-model systems debated.
IONQNYSE
IonQ Inc.

World-leading trapped-ion quantum platform. FY2025 revenue $130M (+202% YoY). Acquiring SkyWater Technology for $1.8B. DARPA Stage B participant. Partners with AWS, Azure, and Google Cloud.

Price
~$37
Target
$68–$100
Upside
+76–170%
⚠ Market cap ~$16B on $130M revenue = extreme P/S. Insider selling noted. Wolfpack Research short report in early 2026.
04 — Sector
Synthetic DNA
TWST · DNA · CRSP
$16.2B → $50B+ by 2030
Synthetic biology enables designing organisms with new capabilities — from medicines and materials to food and data storage at the molecular level.
CRISPR/Cas9 received its first FDA approval in November 2023 — Casgevy for sickle cell disease. The era of gene therapy has officially begun.
AI is accelerating drug discovery: companies combining synthetic DNA with AI-driven protein modeling are cutting R&D timelines by years, not months.
Long regulatory timelines (FDA Phase I–III). Reimbursement uncertainty. Manufacturing complexity. Clinical trial failure rates remain high.
TWSTNASDAQ
Twist Bioscience

Manufactures synthetic DNA on silicon chips — enabling unprecedented precision and scale. FY25 revenue $376M (+20% YoY). Targeting EBITDA breakeven Q4 2026. 2,484 customers across pharma, ag, and data storage.

Price
~$49
Target
$52
Upside
+6%
⚠ J.P. Morgan holds a Sell rating. Near-term profitability not yet proven. NGS customer concentration risk.
DNANYSE
Ginkgo Bioworks

Programs microbes and cells for pharma, agriculture, and materials — called 'the AWS for biology.' Pivoting to AI-bio platform licensing. Founder-led with large IP library. Restructuring to cut costs.

Price
~$3–5
Target
Speculative
Upside
High Beta
⚠ Significant restructuring underway. Stock down sharply from highs. Revenue model still evolving. High dilution risk.
CRSPNASDAQ
CRISPR Therapeutics

Pioneer of CRISPR/Cas9 gene editing. Casgevy (with Vertex) is the first-ever approved CRISPR therapy — treating sickle cell disease. Advancing CAR-T cancer and Type 1 diabetes programs. $1B+ cash.

Price
~$55
Target
Pipeline
Upside
Moderate
⚠ No near-term profitability. Casgevy reimbursement ramp slow. Competitive gene-editing landscape evolving rapidly.
05 — Sector
Nuclear Energy (SMR)
OKLO · SMR · BWXT
AI power surge · $2.6T infra
AI data centers, EV charging, and manufacturing re-shoring are creating a power demand surge the grid cannot meet with solar and wind alone.
Nuclear is the ONLY 24/7 carbon-free energy source that scales — making Small Modular Reactors the most strategic energy investment of the decade.
Major tech is signing nuclear deals: Meta (Oklo — 1.2GW campus), Microsoft (Three Mile Island restart), Amazon, Google (Kairos Power).
SMR licensing takes years. Best-case first plants in 2027–2028. OKLO and SMR have zero revenue today. Capital-intensive with heavy dilution risk.
OKLONYSE
Oklo Inc.

Sam Altman-backed Aurora compact fast-fission reactors (15–100 MWe). Landmark 1.2GW Meta campus deal signed. 12GW+ pipeline with Switch. $1.2B cash. First plant targeted 2027. Surged 1,000%+ in 2025.

Price
~$65–90
Target
$113
Upside
+74%
⚠ Zero revenue. Regulatory approval pending. ATH $193 in Oct 2025, now pulled back 50%+. Dilution risk via capital raises.
SMRNYSE
NuScale Power

First-ever NRC-approved SMR design in the U.S. (VOYGR). 77 MWe per module, scalable to 924 MWe. Engineering services revenue growing. Stock down ~30% in 2025 before recovering +20% YTD 2026.

Price
~$10–12
Target
Limited
Upside
High
⚠ Large investor exit pressure. First commercial projects face delays. NRC approval does not guarantee on-schedule deployment.
BWXTNYSE
BWX Technologies

Profitable infrastructure play — manufacturer and service provider for the nuclear industry. Supplies U.S. Navy nuclear propulsion and medical radioisotopes. CEO cited 'accelerating demand' across defense, clean energy, and medical.

Price
~$100+
Target
Strong
Upside
+Div
⚠ Less speculative upside than pure-play SMR names. Exposed to government contract renewal cycles over time.
06 — Sector
Crypto Infrastructure
BMNR · APLD · CRCL
BTC: $0 → $1T+ asset class
Bitcoin has gone from zero to a $1T+ asset class in 15 years — now held by sovereign wealth funds, pension funds, and corporate treasuries globally.
Stablecoins (USDC, USDT) are becoming global payment infrastructure. Circle processed billions in settlements. These are the picks and shovels of crypto.
Applied Digital pivoted from crypto mining to hyperscale AI data centers — achieving 250% YoY revenue growth with $16B in contracted lease revenue.
Directly correlated to Bitcoin/Ethereum prices. BMNR trades as leveraged ETH. Regulatory uncertainty remains. Among the most volatile equities in existence.
BMNRAMEX
BitMine Immersion

Largest corporate Ethereum holder — 4.4M+ ETH (~3.5% of total supply). Chaired by Tom Lee (Fundstrat). Targeting 5% of all ETH. Invested $200M in Beast Industries (MrBeast). Backed by ARK's Cathie Wood.

Price
~$21
Target
~$60
Upside
+185%
⚠ Down 80%+ from $161 ATH. Pure leverage to ETH price. Share dilution risk. No operating profitability.
APLDNASDAQ
Applied Digital Corp.

AI-first hyperscale data center and HPC infrastructure. Pivoted from crypto mining to AI. Q2 FY26: $126M revenue (+250% YoY). $16B in contracted lease revenue pipeline. 10/10 analyst Buy ratings — zero holds.

Price
~$28
Target
$35–51
Upside
+25–87%
⚠ Still unprofitable. Dependent on hyperscaler leases materializing. CoreWeave financing concerns hit stock in early 2026.
CRCLNYSE
Circle Internet Group

Issuer of USDC — world's 2nd-largest stablecoin. Platform and infrastructure for stablecoin and blockchain payments. Q4 2025 EPS $0.43 vs $0.16 estimate — massive beat. Bernstein 12-month target: $230.

Price
~$100
Target
$230
Upside
+75%+
⚠ Revenue dependent on interest rates (reserve income). Stablecoin regulation still evolving. Tether dominates market share globally.
07 — Strategy

PORTFOLIO
CONSTRUCTION

How to size, manage, and protect speculative allocations without losing sleep.

Portfolio Approach
Sleeve Sizing
Cap speculative allocation at 5–15% of total portfolio. Client risk tolerance dependent. This is asymmetric upside capital — sized accordingly.
Equal Weight Within Sleeves
Split each sector evenly across 3 stocks. No single-stock concentration. Diversification within the theme is essential.
Rebalancing Cadence
Review quarterly. Trim outperformers, add to underperformers within thesis. Don't let winners balloon to 50%+ of the sleeve.
Stop-Loss Discipline
Consider 25–40% stop-loss on individual names given extreme volatility. Speculative positions can halve in days.
Time Horizon
3–5 year minimum. These are not short-term trades. Expect painful multi-year drawdowns during the journey.
Key Risks to Monitor
All Sectors
Macro risk-off events (rate hikes, recession) crush speculative growth stocks disproportionately. These names can drop 50%+ in a broad selloff.
Quantum
P/S multiples of 30–100x require flawless execution. Any guidance miss = 30–50% single-day drops are possible.
Synthetic DNA
Clinical trial failures are binary events. A single Phase III failure can cut a biotech in half overnight — no warning, no exit window.
Nuclear
Regulatory delays endemic. OKLO and SMR could be years from first revenue. Cash burn and dilution risk must be tracked.
Crypto
Bitcoin price drives everything. A 50% BTC crash would devastate BMNR and pressure APLD. Regulatory reversals could be catastrophic.
Insider Signal
Insiders across quantum names net-sold ~$615M in shares over the past year. When those closest to the business are selling at scale, pay attention.

THE BEST INVESTMENTS OF THE NEXT DECADE LOOK CRAZY TODAY.

Amazon at $1. Netflix as a DVD mailer. Tesla as a startup. Bitcoin at $0.08.

Speculation is not recklessness — it's the price of admission to the next generation of wealth.

Quantum Computing
RGTI · QBTS · IONQ
Synthetic DNA
TWST · DNA · CRSP
Nuclear Energy (SMR)
OKLO · SMR · BWXT
Crypto Infrastructure
BMNR · APLD · CRCL

CONFIDENTIAL — FOR INVESTMENT DISCUSSION PURPOSES ONLY. THIS IS NOT A SOLICITATION TO BUY OR SELL ANY SECURITY. ALL PRICE TARGETS AND ANALYST ESTIMATES SOURCED FROM PUBLICLY AVAILABLE THIRD-PARTY RESEARCH. PAST PERFORMANCE DOES NOT GUARANTEE FUTURE RESULTS. SPECULATIVE INVESTMENTS CARRY SUBSTANTIAL RISK OF LOSS. CONSULT A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.